Unique molecular features and clinical outcomes in young patients with non-small cell lung cancer harboring ALK fusion genes.

ABSTRACT:

Purpose

This study aimed to determine the molecular features and clinical outcomes of young patients with non-small cell lung cancer (NSCLC) harboring ALK fusion genes.

Methods

We interrogated the genomic profile of 1652 patients with lung cancer who underwent targeted next-generation sequencing to screen for candidate oncogenic drivers using histological specimens acquired from January 2016 to December 2018.

Results

ALK fusions were identified in 101 NSCLC patients, and 52 of them were diagnosed before the age of 50 years (52/367, 14.2%). Of the 52 patients with early-onset disease, 22 (42.3%) were male and 43 (82.7%) never smoked; the median patient age was 44 years (range 28-50 years). The most frequently occurring ALK fusion partner was EML4, which was identified

SUBMITTER: Tian P 

PROVIDER: S-EPMC11804450 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature